Cell Culture Media Market 2030: A Deep Dive into North America's Dominance

The global cell culture media market was valued at approximately USD 4.73 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 12.54% from 2024 to 2030. Cell culture media refers to a mixture, typically in liquid or gel form, that contains the necessary nutrients, vitamins, amino acids, salts, and other compounds required to support and regulate the growth of cells or microorganisms. These cells and microorganisms are used in various applications, including the manufacturing of biopharmaceuticals.

Cell culture media plays an essential role in the biopharmaceutical industry by supporting the growth of cells, which are used for the production of vaccines, biologics, and other therapeutic products. As a result, it is considered one of the most important components in biopharmaceutical manufacturing. This segment of the market is expanding rapidly, driven by several key factors, including the rising demand for biopharmaceuticals, favorable government policies, and increased investment in research and development (R&D).

The COVID-19 pandemic has had a significant impact on the market, further accelerating the demand for cell culture media. The outbreak underscored the importance of cell-based technologies, especially for vaccine development, leading to an increased focus on cell culture media used in vaccine production. The pandemic prompted advancements in vaccine technology, with cell culture systems being widely adopted for the rapid production of vaccines.

Gather more insights about the market drivers, restrains and growth of the Global Cell Culture Media Market

Regional Insights

North America
North America led the global cell culture media market in 2023, holding a significant revenue share of 37.58%. This dominant position is primarily driven by the robust growth in the pharmaceutical and biotechnology sectors, which heavily rely on cell culture techniques for the development of various biopharmaceutical products. Additionally, the region has seen a surge in regulatory approvals for cell culture-based vaccines, contributing to the demand for high-quality culture media. Another key factor fueling market growth in North America is the rising incidence of diseases like cancer, which has led to an increased need for novel therapeutic solutions, including cell-based therapies and vaccines.

Furthermore, North America benefits from significant investments and funding in cell-based research and development. The strong presence of leading biopharmaceutical companies, research institutions, and cutting-edge healthcare infrastructure in the U.S. and Canada supports the ongoing advancements in cell culture technologies. This investment in R&D, combined with an established market for biopharmaceuticals, ensures that North America remains a critical hub for the growth of the cell culture media market.

Asia Pacific
The Asia Pacific region is expected to experience the fastest growth in the cell culture media market, with an estimated compound annual growth rate (CAGR) of 14.92% during the forecast period. Several factors are driving this rapid growth, particularly the increasing awareness of the benefits and applications of cell culture techniques in the biopharmaceutical industry. As awareness grows, more companies and research institutions in Asia Pacific are adopting cell culture-based technologies for vaccine production, gene therapy, and other biotechnological advancements.

In addition to this awareness, key market players are actively expanding their operations in Asia Pacific countries, recognizing the region’s high growth potential. These strategic moves are expected to capture significant market share and open up lucrative opportunities. For example, in December 2021, Fujifilm Irvine Scientific, Inc. announced the construction of a new bioprocessing center in China. This facility is designed to enhance the optimization of cell culture media, specifically for the development of biotherapeutic drugs, vaccines, and advanced therapies. The establishment of such bioprocessing centers in Asia Pacific is expected to further boost the demand for high-quality cell culture media and support the region’s rapid market growth.

The Asia Pacific market is also supported by favorable government policies, increasing healthcare investments, and a growing pharmaceutical and biotechnology sector, all of which are expected to accelerate the adoption of cell culture technologies and media in the coming years. This makes the region a key area of focus for market players looking to expand their global presence.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global preparative and process chromatography market size was estimated at USD 9.5 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 9.08% over the forecast period.
• The global research antibodies market size was valued at USD 1.59 billion in 2023 and is expected to grow at compound annual growth rate (CAGR) of 4.76% from 2024 to 2030.

Key Cell Culture Media Company Insights

Key players in cell culture media market are implementing various strategies including partnership, merger and acquisition, geographical expansion, and strategic collaboration to expand their market presence. In July 2023, Merck KGaA invested USD 24.38 million to boost cell culture media production in the U.S. This development expanded the production capacity of the Lenexa facility to manufacture cell culture media.

Key Cell Culture Media Companies:

The following are the leading companies in the cell culture media market. These companies collectively hold the largest market share and dictate industry trends.

• Sartorius AG
• Danaher
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• FUJIFILM Corporation
• Lonza
• BD
• STEMCELL Technologies
• Cell Biologics, Inc.
• PromoCell GmbH

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.